<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="doi: 10.1016/j.bioorg.2020.104269104269 : Review Article Druggable targets of SARS-CoV-2 and" exact="treatment" post="opportunities for COVID-19 FaheemaKumarBanoth KaranaSekharKondapalli Venkata Gowri ChandrabKunjiappanSelvarajcJamalisJoazaizulfazlidBalaÃ±a-FouceRafaeleTekwaniBabu L.fSankaranarayananMurugesanaâ�Ž[a],"/>
 <result pre="targeted by a proven inhibitor of TMPRSS2, camostat. The current" exact="treatment" post="strategy includes repurposing of existing drugs that were found"/>
 <result pre="druggable targets of SARS CoV-2, new drug discovery, development, and" exact="treatment" post="opportunities for COVID-19. Keywords SARS-CoV-2 Coronavirus RNA virus Respiratory"/>
 <result pre="Polymerase Chain Reaction (RT-qPCR), Computed Tomography (CT) scans to immunological" exact="detection" post="kits [9]. SARS-CoV-2 is an enveloped, single-stranded positive-sense RNA"/>
 <result pre="In general, three approaches were followed for the discovery and" exact="treatment" post="options for the pathogenic coronaviruses- SARS and MERS [12]."/>
 <result pre="for the current pathogenic SARS-CoV-2. The first approach is the" exact="testing" post="of broad-spectrum antiviral agents (mostly drugs) that have been"/>
 <result pre="that measures the effects of these compounds on virus yields," exact="infection" post="rates, virus entry, and plaque formation. Some of the"/>
 <result pre="second approach to the anti-coronavirus drug discovery involves the in-silico" exact="screening" post="of chemical libraries that contains a large number of"/>
 <result pre="that contains a large number of compounds. Rapid, high-throughput virtual" exact="screening" post="(HTVS) of a large number of compounds is possible"/>
 <result pre="and EK1 were also found to effectively inhibit 2019-nCoV pseudovirus" exact="infection" post="in 293Â T cells with IC50 values of 0.98Â"/>
 <result pre="linker/spacer GSGSG-PGE4. EK1C4 also exhibited potent activity against SARS-CoV-2 pseudovirus" exact="infection" post="and live SARS-CoV-2 infection in vitro with IC50 values"/>
 <result pre="exhibited potent activity against SARS-CoV-2 pseudovirus infection and live SARS-CoV-2" exact="infection" post="in vitro with IC50 values of 15.8Â nM and"/>
 <result pre="the prophylactic and post-infection potential of EK1C4 on the HCoV-OC43" exact="infection" post="mouse model. The studies revealed that EK1C4 was effective"/>
 <result pre="effective prophylactically up to 12Â h before challenging with the" exact="infection" post="at a dose of 0.5Â mg/kg intranasally, suggesting good"/>
 <result pre="(kcal/mol), are given in Fig. 6 . An advantage of" exact="screening" post="clinical molecules is that the safety and adverse effects"/>
 <result pre="remdesivir diphosphate, the RdRp inhibitor under clinical trials for the" exact="treatment" post="of COVID-19, to SARS CoV-2 nsp12, was investigated based"/>
 <result pre="of the HCV polymerase. Sofosbuvir has been approved for the" exact="treatment" post="of chronic HCV infection [66]. The catalytic site of"/>
 <result pre="Sofosbuvir has been approved for the treatment of chronic HCV" exact="infection" post="[66]. The catalytic site of SARS CoV-2 nsp13 shows"/>
 <result pre="SARS CoV-2 RdRp and are excellent drug candidates for the" exact="treatment" post="of COVID-19. Fig. 9 Antiviral drugs targeting RdRp functions."/>
 <result pre="strategy encompassing structure-based drug design, virtual screening, and high throughput" exact="screening" post="to repurpose existing drugs or agents to target Mpro"/>
 <result pre="the crystal structure of SARS-CoV-2 Mpro with N3, a virtual" exact="screening" post="study identified cinanserin, a serotonin antagonist, as a promising"/>
 <result pre="against SARS-CoV-2 Mproin vitro (IC50Â =Â 125Â ÂµM). A high-throughput" exact="screening" post="study consisting of approved drugs, natural products, and clinical"/>
 <result pre="the promising potential of atazanavir and atazanavir/ritonavir combination for the" exact="treatment" post="of COVID-19 [76]. Through a combination of molecular docking"/>
 <result pre="in countering the strength of host immune response to viral" exact="infection" post="by shutting down crucial pathways [78], [79], [80]. Currently,"/>
 <result pre="in-house database of Chinese medicine and natural products. The virtual" exact="screening" post="study identified ribavirin, valganciclovir, Î²-thymidine, and natural products Platycodin"/>
 <result pre="antiviral molecule that was developed by Gilead Sciences for the" exact="treatment" post="of the Ebola virus [85]. Remdesivir is in the"/>
 <result pre="potential of remdesivir in the rhesus macaque model of MERS-CoV" exact="infection" post="[88]. Remdesivir potently inhibited the replication of SARS-CoV and"/>
 <result pre="SARS-CoV-2 in vitro. Remdesivir was effective in blocking the viral" exact="infection" post="in Vero E6 cells infected with nCoV-2019BetaCoV/Wuhan/WIV04/2019 (EC50Â =Â"/>
 <result pre="placebo-controlled study evaluating the effectiveness of intravenous remdesivir for the" exact="treatment" post="of COVID-19 was recently published. The study findings revealed"/>
 <result pre="placebo-treated group [92]. Recently, Gilead Sciences announced that a 5-day" exact="treatment" post="course of remdesivir was associated with significantly greater clinical"/>
 <result pre="two structurally related protease inhibitors that were developed for the" exact="treatment" post="of (HIV). Lopinavir exhibited higher selectivity, about 10-fold against"/>
 <result pre="registered in ClinicalTrial.gov on clinical evaluation of lopinavir/ritonavir for the" exact="treatment" post="of COVID-19. The results posted on a recently conducted"/>
 <result pre="3.1.3 Favipiravir Favipiravir is an antiviral drug approved for the" exact="treatment" post="of the influenza virus. Favipiravir is a prodrug that"/>
 <result pre="compare the clinical effectiveness of favipiravir and lopinavir/ritonavir as a" exact="treatment" post="strategy for COVID-19. The study findings revealed that favipiravir"/>
 <result pre="for COVID-19. The study findings revealed that favipiravir had better" exact="treatment" post="outcomes on COVID-19 in terms of viral clearance and"/>
 <result pre="of favipiravir based on its previous clinical trials for influenza" exact="treatment" post="[109] may be useful for determining the appropriate doses"/>
 <result pre="be useful for determining the appropriate doses and course of" exact="treatment" post="for COVID-19. 3.1.4 Ribavirin Ribavirin, a guanosine analog, has"/>
 <result pre="Ribavirin Ribavirin, a guanosine analog, has been used for the" exact="treatment" post="of RNA viruses like hepatitis and respiratory syncytial virus."/>
 <result pre="the combination of ribavirin and interferon therapy as an effective" exact="treatment" post="strategy for SARS-CoV and MERS-CoV [111], [112], [113]. Recently,"/>
 <result pre="are underway to evaluate the efficacy of ribavirin in the" exact="treatment" post="of COVID-19 [62]. 3.1.5 Other antiviral drugs Other antivirals"/>
 <result pre="darunavir/cobicistat combination (Fig. 19 ). Umifenovir is used for the" exact="treatment" post="of influenza in Russia and China. Umifenovir exhibits its"/>
 <result pre="into the host cell [114]. Oseltamivir, also used for the" exact="treatment" post="of influenza viruses, acts as a neuraminidase inhibitor, preventing"/>
 <result pre="particles [115]. Darunavir is a protease inhibitor approved for the" exact="treatment" post="of HIV, and cobicistat prevents the catabolism of darunavir"/>
 <result pre="to the class of glycopeptide antibiotic is used for the" exact="treatment" post="of gram-positive bacterial infections. The previous report suggested that"/>
 <result pre="highlighted the importance of azithromycin for the management of SARS-CoV-2" exact="infection" post="[117]. A total of 36 patients were enrolled for"/>
 <result pre="SARS-CoV-2. Fig. 20 Antibiotics that are being explored for the" exact="treatment" post="of COVID-19. 3.2.3 Carrimycin Carrimycin, a macrolide antibiotic, is"/>
 <result pre="treating patients with COVID-19. Carrimycin has been patented for the" exact="treatment" post="of mycobacterial infections (European patent EP 3384915 A1). However,"/>
 <result pre="of chloroquine against the SARS-CoV-2. Chloroquine effectively blocked the viral" exact="infection" post="with a high selectivity index (EC50Â =Â 1.13Â ÂµM)"/>
 <result pre="Gao et al., in a recent publication, disclosed that chloroquine" exact="treatment" post="offered superior efficacy than control treatment in a trial"/>
 <result pre="publication, disclosed that chloroquine treatment offered superior efficacy than control" exact="treatment" post="in a trial that involved a hundred infected patients"/>
 <result pre="in the room- Can hydroxychloroquine also be used for the" exact="treatment" post="of Covid-19? A recent report demonstrated that hydroxychloroquine is"/>
 <result pre="its proven immunomodulatory properties, hydroxychloroquine can act as an ideal" exact="treatment" post="intervention in severely ill cases where cytokine storm is"/>
 <result pre="chloroquine or hydroxychloroquine with or without a macrolide for the" exact="treatment" post="of COVID-19 was published. The study comprising data from"/>
 <result pre="600 hospitals in six continents concluded that chloroquine or hydroxychloroquine" exact="treatment" post="afforded no protection to COVID-19 patients and was associated"/>
 <result pre="several proteolytic enzymes. Evidence suggests that viral entry, replication, and" exact="infection" post="requires an acidic environment in the endosome-lysosomes and the"/>
 <result pre="class of drugs, is an antiprotozoal agent used for the" exact="treatment" post="of various protozoal and helminthic infections [134]. Apart from"/>
 <result pre="to inhibit the replication of SARS-CoV-2 in vitro[139]. A single" exact="treatment" post="of ivermectin at the dose of 5Â ÂµM resulted"/>
 <result pre="COVID-19. Fig. 21 Antiprotozoal drugs that are being repurposed for" exact="treatment" post="of COVID-19. 3.4 Fusion inhibitors 3.4.1 Camostat As previously"/>
 <result pre="protease inhibitor that has been approved in Japan for the" exact="treatment" post="of pancreatitis, was shown to block the cellular entry"/>
 <result pre="clinical trials (NCT04338906, NCT04321096) to prove its efficacy for the" exact="treatment" post="of COVID-19. 3.4.2 Nafamostat Following the footsteps of camostat"/>
 <result pre="(ARDS) [143]. Therefore, corticosteroids can be considered as an adjunct" exact="treatment" post="option. However, currently, corticosteroid therapy is a topic of"/>
 <result pre="in a retrospective study, it was demonstrated that early, low-dose" exact="treatment" post="intervention with corticosteroids was associated with quicker improvement of"/>
 <result pre="and additional evidence is needed to be considered as a" exact="treatment" post="intervention. Currently, a clinical trial is underway to evaluate"/>
 <result pre="efficacy of dexamethasone in patients with ARDS secondary to SARS-CoV-2" exact="infection" post="(NCT04325061). Zhou et al. demonstrated that inflammatory and pro-inflammatory"/>
 <result pre="colony-stimulating factor (GM-CSF) and IL-6 are highly expressed following viral" exact="infection" post="[146]. Therefore, blocking GM-CSF and IL-6 receptors can reduce"/>
 <result pre="Baricitinib has been proposed as a potential drug for the" exact="treatment" post="of COVID-19 [147]. AP-2 associated protein kinase 1 (AAK1)"/>
 <result pre="appears to be a double-edged sword with respect to the" exact="treatment" post="of COVID-19 [148]. Interferons are essential soldiers deployed by"/>
 <result pre="Chinese Medicine (TCM) has played a substantial role in the" exact="treatment" post="and prevention of past epidemics. Past clinical studies have"/>
 <result pre="clinical studies have underlined the importance of TCM in the" exact="treatment" post="and prevention of SARS and H1N1 influenza [149], [150]."/>
 <result pre="Table 2[153]. Table 2 Chinese patent medicines recommended under the" exact="diagnosis" post="and treatment protocol for novel Coronavirus Pneumonia (Trial version"/>
 <result pre="Table 2 Chinese patent medicines recommended under the diagnosis and" exact="treatment" post="protocol for novel Coronavirus Pneumonia (Trial version seven) [153]."/>
 <result pre="LianhuaQingwen capsules (granules), ShufengJiedu capsules (granules), FangfengTongsheng pills (granules) Clinical" exact="treatment" post="(confirmed cases) Severe cases Xiyanping injection, Xuebijing injection, Reduning"/>
 <result pre="injection, Shengmai injection, Shenmai injection Ni et al. reported the" exact="treatment" post="of 3 COVID-19 patients in Wuhan with Shuanghuanglian oral"/>
 <result pre="SHL is a patented TCM that is used for the" exact="treatment" post="of cough, cold, and fever. The symptoms of all"/>
 <result pre="TNF-Î± and IL-6 [155]. Though TCM seems to be a" exact="treatment" post="strategy for COVID-19, the safety aspects of TCM needs"/>
 <result pre="has shown the results required for the approval for the" exact="treatment" post="of COVID-19 or protection against SARS-CoV-2 infections. This review"/>
 <result pre="as an understanding of the pathogenesis of the disease. The" exact="treatment" post="approaches that are currently being explored have also been"/>
 <result pre="highlighted. The drugs that are currently being explored for the" exact="treatment" post="of COVID-19 is summarized in Table 3 . Table"/>
 <result pre="the Drugs/investigational agents that are currently being explored for the" exact="treatment" post="of COVID-19. Compound name Category Potency against SARS-CoV-2 (in"/>
 <result pre="needs further investigationMaxillofac. Plast. Reconstr. Surg.422020910.1186/s40902-020-00254-732289035 9LiX.GengM.PengY.MengL.LuS.Molecular immune pathogenesis and" exact="diagnosis" post="of COVID-19J. Pharm. Anal.202010.1016/j.jpha.2020.03.001 10WuC.LiuY.YangY.ZhangP.ZhongW.WangY.WangQ.XuY.LiM.LiX.ZhengM.ChenL.LiH.Analysis of therapeutic targets for"/>
 <result pre="ebola, hendra, and nipah viruses by using a novel high-throughput" exact="screening" post="assayAm Soc Microbiol.201410.1128/JVI.03050-13 17DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.JahrlingP.B.LaidlawM.JohansenL.M.Lear-RooneyC.M.GlassP.J.HensleyL.E.FriemanM.B.Repurposing of clinically developed drugs for"/>
 <result pre="screening assayAm Soc Microbiol.201410.1128/JVI.03050-13 17DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.JahrlingP.B.LaidlawM.JohansenL.M.Lear-RooneyC.M.GlassP.J.HensleyL.E.FriemanM.B.Repurposing of clinically developed drugs for" exact="treatment" post="of middle east respiratory syndrome coronavirus infectionAm Soc Microbiol.201410.1128/AAC.03036-14"/>
 <result pre="of human coronavirus spikeSci. Adv.5201910.1126/sciadv.aav4580 28XiaS.LiuM.WangC.XuW.LanQ.FengS.QiF.BaoL.DuL.LiuS.QinC.SunF.ShiZ.ZhuY.JiangS.LuL.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
 <result pre="Sci. USA1112014E3900E390910.1073/pnas.132370511125197083 60MorseJ.S.LalondeT.XuS.LiuW.R.Learning from the past: possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019-nCoVChemBioChem21202073073810.1002/cbic.20200004732022370"/>
 <result pre="of ebselen, a glutathione peroxidase mimic, for the prevention and" exact="treatment" post="of noise-induced hearing loss, in: Semin. Hear., Â© Thieme"/>
 <result pre="Pneumo-, and ParamyxovirusesSci. Rep.7201710.1038/srep43395 88de WitE.FeldmannF.CroninJ.JordanR.OkumuraA.ThomasT.ScottD.CihlarT.FeldmannH.Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc. Natl."/>
 <result pre="rhesus macaques infected with SARS-CoV-2Nature202010.1038/s41586-020-2423-5 92BeigelJ.H.TomashekK.M.DoddL.E.MehtaA.K.ZingmanB.S.KalilA.C.HohmannE.ChuH.Y.LuetkemeyerA.KlineS.Lopez de CastillaD.FinbergR.W.DierbergK.TapsonV.HsiehL.PattersonT.F.ParedesR.SweeneyD.A.ShortW.R.TouloumiG.LyeD.C.OhmagariN.OhM.Ruiz-PalaciosG.M.BenfieldT.FÃ¤tkenheuerG.KortepeterM.G.AtmarR.L.CreechC.B.LundgrenJ.BabikerA.G.PettS.NeatonJ.D.BurgessT.H.BonnettT.GreenM.MakowskiM.OsinusiA.NayakS.LaneH.C.Remdesivir for the" exact="treatment" post="of covid-19 â€&quot; preliminary reportN. Engl. J. Med.202010.1056/nejmoa2007764 93D."/>
 <result pre="Chemother.5820144875488410.1128/AAC.03011-1424841269 99ChanJ.F.-W.YaoY.YeungM.-L.DengW.BaoL.JiaL.LiF.XiaoC.GaoH.YuP.CaiJ.-P.ChuH.ZhouJ.ChenH.QinC.YuenK.-Y.Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ. Infect."/>
 <result pre="in activation of the antiviral agent T-705 (favipiravir)Mol. Pharmacol.84201361562910.1124/mol.113.08724723907213 104OestereichL.LÃ¼dtkeA.WurrS.RiegerT.MuÃ±oz-FontelaC.GÃ¼ntherS.Successful" exact="treatment" post="of advanced Ebola virus infection with T-705 (favipiravir) in"/>
 <result pre="agent T-705 (favipiravir)Mol. Pharmacol.84201361562910.1124/mol.113.08724723907213 104OestereichL.LÃ¼dtkeA.WurrS.RiegerT.MuÃ±oz-FontelaC.GÃ¼ntherS.Successful treatment of advanced Ebola virus" exact="infection" post="with T-705 (favipiravir) in a small animal modelAntiviral Res.1052014172110.1016/j.antiviral.2014.02.01424583123"/>
 <result pre="in Guinea, PLOS Med. 13 (2016) e1001967. doi: 10.1371/journal.pmed.1001967. 108CaiQ.YangM.LiuD.ChenJ.ShuD.XiaJ.LiaoX.GuY.CaiQ.YangY.ShenC.LiX.PengL.HuangD.ZhangJ.ZhangS.WangF.LiuJ.ChenL.ChenS.WangZ.ZhangZ.CaoR.ZhongW.LiuY.LiuL.Experimental" exact="treatment" post="with favipiravir for COVID-19: an open-label control studyEngineering202010.1016/j.eng.2020.03.007 109DuY.-X.ChenX.-P.Favipiravir:"/>
 <result pre="a broad-spectrum antiviral: an updateAntiviral Res.1072014849410.1016/j.antiviral.2014.04.00624769245 115Bardsley-ElliotA.NobleS.OseltamivirDrugs58199985186010.2165/00003495-199958050-0000710595865 116CapettiA.CossuM.V.RizzardiniG.Darunavir/cobicistat for the" exact="treatment" post="of HIV-1: A new era for compact drugs with"/>
 <result pre="to resistanceExpert Opin. Pharmacother.1620152689270210.1517/14656566.2015.110963226612518 117GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontT.HonorÃ©S.ColsonP.ChabriÃ¨reE.La ScolaB.RolainJ.-M.BrouquiP.RaoultD.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt."/>
 <result pre="Dis.1201631732610.1021/acsinfecdis.5b00030 120DelvecchioR.HigaL.M.PezzutoP.ValadÃ£oA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.M.AliotaM.T.CaineE.A.OsorioJ.E.BellioM.Oâ€™ConnorD.H.RehenS.De AguiarR.S.SavarinoA.CampanatiL.TanuriA.Chloroquine, an endocytosis blocking agent, inhibits zika virus" exact="infection" post="in different cell modelsViruses8201610.3390/v8120322 121FreibergA.N.WorthyM.N.LeeB.HolbrookM.R.Combined chloroquine and ribavirin treatment"/>
 <result pre="virus infection in different cell modelsViruses8201610.3390/v8120322 121FreibergA.N.WorthyM.N.LeeB.HolbrookM.R.Combined chloroquine and ribavirin" exact="treatment" post="does not prevent death in a hamster model of"/>
 <result pre="and chloroquineVirology138198433233510.1016/0042-6822(84)90356-86093369 124VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.2200510.1186/1743-422X-2-69 125GaoJ.TianZ.YangX.Breakthrough: Chloroquine phosphate has shown apparent"/>
 <result pre="spreadVirol. J.2200510.1186/1743-422X-2-69 125GaoJ.TianZ.YangX.Breakthrough: Chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBiosci. Trends142020727310.5582/bst.2020.0104732074550 126LiuJ.CaoR.XuM.WangX.ZhangH.HuH.LiY.HuZ.ZhongW.WangM.Hydroxychloroquine,"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov.620201610.1038/s41421-020-0156-032194981 127YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.LiuX.ZhaoL.DongE.SongC.ZhanS.LuR.LiH.TanW.LiuD.In vitro antiviral activity and projection"/>
 <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect."/>
 <result pre="coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 128SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and hydroxychloroquine in the" exact="treatment" post="of COVID-19 with or without diabetes: A systematic search"/>
 <result pre="Rev.202010.1016/j.dsx.2020.03.011 129MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.Hydroxychloroquine or chloroquine with or without a macrolide for" exact="treatment" post="of COVID-19: a multinational registry analysisLancet202010.1016/S0140-6736(20)31180-6 130Chief Investigators of"/>
 <result pre="acidification by chloroquine analogs as a promising strategy for the" exact="treatment" post="of emerging viral diseasesPharmacol. Res. Perspect.5201710.1002/prp2.293 134FoxL.M.SaravolatzL.D.Nitazoxanide: a new"/>
 <result pre="antiviral agentAntiviral Res.11020149410310.1016/j.antiviral.2014.07.01425108173 136RossignolJ.F.Nitazoxanide, a new drug candidate for the" exact="treatment" post="of Middle East respiratory syndrome coronavirusJ. Infect. Public Health9201622723010.1016/j.jiph.2016.04.00127095301"/>
 <result pre="in vitroAntiviral Res.178202010478710.1016/j.antiviral.2020.104787 140Al-HoraniR.A.DesaiU.R.Recent advances on plasmin inhibitors for the" exact="treatment" post="of fibrinolysis-related disordersMed. Res. Rev.3420141168121610.1002/med.2131524659483 141YamamotoM.MatsuyamaS.LiX.TakedaM.KawaguchiY.InoueJ.I.MatsudaZ.Identification of nafamostat as"/>
 <result pre="which is expected to prevent the transmission of new coronavirus" exact="infection" post="(COVID-19)|THE INSTITUTE OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO,"/>
 <result pre="Wuhan , China, (2020). 144RussellC.D.MillarJ.E.BaillieJ.K.Clinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injuryLancet395202047347510.1016/S0140-6736(20)30317-232043983 145Y. Wang, W. Jiang, Q."/>
 <result pre="Dong, Q. Tong, Early, low-dose and short-term application of corticosteroid" exact="treatment" post="in patients with severe COVID-19 pneumonia: single-center experience from"/>
 <result pre="a new coronavirus, BioRxiv. (2020) 2020.02.12.945576. doi:10.1101/2020.02.12.945576. 147RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet3952020e30e3110.1016/S0140-6736(20)30304-432032529 148FavalliE.G.BiggioggeroM.MaioliG.CaporaliR.Baricitinib for COVID-19: a"/>
 <result pre="150ChenZ.NakamuraT.Statistical evidence for the usefulness of Chinese medicine in the" exact="treatment" post="of SARSPhyther. Res.18200459259410.1002/ptr.1485 151J. ling Ren, A.H. Zhang, X.J."/>
 <result pre="Res. 155 (2020) 104743. doi:10.1016/j.phrs.2020.104743. 152YangY.IslamM.S.WangJ.LiY.ChenX.Traditional Chinese medicine in the" exact="treatment" post="of patients infected with 2019-new coronavirus (SARS-CoV-2): a review"/>
</results>
